Report of Foreign Issuer (6-k)
August 17 2018 - 8:54AM
Edgar (US Regulatory)
PRIVILEGED AND CONFIDENTIAL
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
August 2018
Commission file number: 001-36288
Akari Therapeutics, Plc
(Translation of registrant's name into English)
75/76 Wimpole Street
London W1G 9RT
United Kingdom
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will
file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F
x
Form
40-F
¨
Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulations S-T Rule 101(b)(1):_____
Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulations S-T Rule 101(b)(7):_____
CONTENTS
On August 17, 2018,
Akari Therapeutics, Plc, (the “Company”) issued a press release announcing first quarter 2018 financial results and
highlights on its clinical development programs. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated
herein by reference.
The statements under “First Quarter
2018 Financial Results”, the accompanying financial statements and “Forward Looking Statements” of Exhibit 99.1
are hereby incorporated by reference into all effective registration statements filed by the Company under the Securities Act of
1933.
Exhibit No.
99.1
|
Press Release dated August 17, 2018.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
Akari Therapeutics, Plc
|
|
|
(Registrant)
|
|
|
|
|
|
|
By:
|
/s/ Clive Richardson
|
|
|
Name:
|
Clive Richardson
|
|
|
|
Interim Chief Executive Officer and Chief Operating Officer
|
|
Date: August 17, 2018
Akari Therapeutics (NASDAQ:AKTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Akari Therapeutics (NASDAQ:AKTX)
Historical Stock Chart
From Apr 2023 to Apr 2024